23-Hydroxybetulinic acid
Based on 1 Customer Validation
23-Hydroxybetulinic acid (Anemosapogenin) is an orally active triterpenoid with broad-spectrum anticancer activity. 23-Hydroxybetulinic acid reduces the levels of Bcl-2 and survivin, elevates the level of Bax, promotes the cleavage/activation of caspase-3 and caspase-9, and induces apoptosis via the endogenous mitochondrial pathway involving cytochrome C release and mitochondrial membrane potential disruption. 23-Hydroxybetulinic acid arrests the cell cycle at S and G1 phases, inhibits cancer cell proliferation, blocks the MAPK signaling pathway, regulates MMP2, and induces autophagic apoptosis by upregulating beclin-1. 23-Hydroxybetulinic acid inhibits the activity and efflux function of P-gp, increases the intracellular accumulation of chemotherapeutic drugs, and synergistically enhances cytotoxicity with Doxorubicin (HY-15142). 23-Hydroxybetulinic acid inhibits the phosphorylation and nuclear translocation of STAT6, blocks M2 macrophage polarization, and reduces M2 macrophage-mediated apoptosis resistance of colon cancer cells. 23-Hydroxybetulinic acid can be used in related studies on chronic myeloid leukemia, hepatocellular carcinoma, sarcoma 180, multidrug-resistant breast cancer, leukemia, Doxorubicin-induced cardiotoxicity, and colorectal cancer.
For research use only. We do not sell to patients.
- Purity : 99.44%
- CAS No.: 85999-40-2
- Formula: C30H48O4
- Molecular Weight:472.70
-
Storage:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
All Caspase Isoforms
More
Biological Activity
Description
|
Caspase 3 |
Caspase-9 |
Bax |
Bcl-2 |
MMP-2 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A2780 | IC50 |
79.12 μM
Compound: 1; HBA
|
Antiproliferative activity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31491611] |
| A-375 | IC50 |
41.99 μM
Compound: 1
|
Antiproliferative activity against human A375 cells after 72 hrs by MTT assay
Antiproliferative activity against human A375 cells after 72 hrs by MTT assay
|
[PMID: 21496972] |
| A-375 | IC50 |
76.3 μM
Compound: 1; HBA
|
Antiproliferative activity against human A375 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human A375 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31491611] |
| A549 | IC50 |
51.44 μM
Compound: 23-HBA; 4
|
Antiproliferative activity against human A549 cells overexpressing NQO1 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human A549 cells overexpressing NQO1 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 35803175] |
| A549 | IC50 |
87.6 μM
Compound: HBA
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 17275295] |
| B16 | IC50 |
18.68 μM
Compound: 1
|
Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay
Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay
|
[PMID: 21496972] |
| B16 | IC50 |
29.87 μM
Compound: 1, HBA
|
Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay
Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay
|
[PMID: 25529742] |
| B16 | IC50 |
29.87 μM
Compound: 1, HBA
|
Antiproliferative activity against mouse B16 cells assessed as growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against mouse B16 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 25984840] |
| B16 | IC50 |
29.87 μM
Compound: HBA
|
Antiproliferative activity against mouse B16 cells after 72 hrs MTT assay
Antiproliferative activity against mouse B16 cells after 72 hrs MTT assay
|
[PMID: 25247772] |
| B16 | IC50 |
83.04 μM
Compound: HBA
|
Cytotoxicity against mouse B16 cells by MTT assay
Cytotoxicity against mouse B16 cells by MTT assay
|
[PMID: 17275295] |
| B16-F10 | IC50 |
24.46 μM
Compound: 1; 23-HBA
|
Antiproliferative activity against mouse B16F10 cells after 72 hrs by MTT assay
Antiproliferative activity against mouse B16F10 cells after 72 hrs by MTT assay
|
[PMID: 30344912] |
| Bel-7402 | IC50 |
39.67 μM
Compound: 1, HBA
|
Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay
Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay
|
[PMID: 25529742] |
| Bel-7402 | IC50 |
39.67 μM
Compound: 1, HBA
|
Antiproliferative activity against human Bel7402 cells assessed as growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human Bel7402 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 25984840] |
| Bel-7402 | IC50 |
39.67 μM
Compound: HBA
|
Antiproliferative activity against human Bel7402 cells after 72 hrs MTT assay
Antiproliferative activity against human Bel7402 cells after 72 hrs MTT assay
|
[PMID: 25247772] |
| Bel-7402 | IC50 |
97.32 μM
Compound: HBA
|
Cytotoxicity against human BEL-7402 cells by MTT assay
Cytotoxicity against human BEL-7402 cells by MTT assay
|
[PMID: 17275295] |
| C6 | IC50 |
99.48 μM
Compound: HBA
|
Cytotoxicity against mouse C6 cells by MTT assay
Cytotoxicity against mouse C6 cells by MTT assay
|
[PMID: 17275295] |
| HeLa | IC50 |
46.22 μM
Compound: 1
|
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 21496972] |
| HeLa | IC50 |
52.39 μM
Compound: 1, HBA
|
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 25529742] |
| HeLa | IC50 |
52.39 μM
Compound: 1, HBA
|
Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 25984840] |
| HeLa | IC50 |
52.39 μM
Compound: HBA
|
Antiproliferative activity against human HeLa cells after 72 hrs MTT assay
Antiproliferative activity against human HeLa cells after 72 hrs MTT assay
|
[PMID: 25247772] |
| HepG2 | IC50 |
41.41 μM
Compound: 1
|
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 21496972] |
| HepG2 | IC50 |
71.84 μM
Compound: 1; HBA
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31491611] |
| HFL1 | IC50 |
75 μM
Compound: 23-HBA; 4
|
Cytotoxicity against human HFL1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Cytotoxicity against human HFL1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 35803175] |
| HL-60 | IC50 |
45.15 μM
Compound: 1, HBA
|
Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
|
[PMID: 25529742] |
| HL-60 | IC50 |
45.15 μM
Compound: 1, HBA
|
Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 25984840] |
| HL-60 | IC50 |
45.15 μM
Compound: HBA
|
Antiproliferative activity against human HL60 cells after 72 hrs MTT assay
Antiproliferative activity against human HL60 cells after 72 hrs MTT assay
|
[PMID: 25247772] |
| HT-29 | IC50 |
54.81 μM
Compound: 23-HBA; 4
|
Antiproliferative activity against human HT-29 cells overexpressing NQO1 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human HT-29 cells overexpressing NQO1 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 35803175] |
| L02 | IC50 |
79.15 μM
Compound: 1; HBA
|
Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31491611] |
| M14 | IC50 |
50 μM
Compound: 7
|
Cytotoxicity against human M14 cells after 48 hrs by MTT assay
Cytotoxicity against human M14 cells after 48 hrs by MTT assay
|
[PMID: 21954959] |
| MCF7 | IC50 |
20.83 μM
Compound: 1; 23-HBA
|
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 30344912] |
| MCF7 | IC50 |
46.61 μM
Compound: 1
|
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 21496972] |
| MCF7 | IC50 |
74.98 μM
Compound: 1; HBA
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31491611] |
| NCI-H596 | IC50 |
58.12 μM
Compound: 23-HBA; 4
|
Antiproliferative activity against NQO1-deficient human NCI-H596 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against NQO1-deficient human NCI-H596 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 35803175] |
In Vitro
23-Hydroxybetulinic acid (0-300 μM; 48 h) potently inhibits proliferation of human chronic myelogenous leukemia K562 cells (IC50 = 39.9 μM) and exhibits lower cytotoxicity against B16, HeLa, and HUVEC cells[1].
23-Hydroxybetulinic acid (0-80 μM; 24 h) induces concentration-dependent S phase cell cycle arrest in human chronic myelogenous leukemia K562 cells after 24 h of treatment, with 80 μM HBA increasing S phase cells to 52.34%[1].
23-Hydroxybetulinic acid (20-80 μM; 24 h) induces concentration-dependent apoptosis in human chronic myelogenous leukemia K562 cells after 24 h of treatment, as detected by Hoechst33342/PI dual staining[1].
23-Hydroxybetulinic acid (20-80 μM; 24 h) significantly disrupts mitochondrial membrane potential in human chronic myelogenous leukemia K562 cells after 24 h of treatment, with 80 μM HBA reducing the red/green fluorescence ratio to 0.38[1].
23-Hydroxybetulinic acid (10-80 μM; 24 h) triggers the intrinsic (mitochondrial) apoptosis pathway in human chronic myelogenous leukemia K562 cells after 24 h of treatment, via concentration-dependent modulation of pro- and anti-apoptotic proteins and activation of caspases[1].
23-Hydroxybetulinic acid (1.25-20 μM; 48-72 h) inhibits viability of Huh-7, Hep3B, and Li-7 human HCC cells in a time- and concentration-dependent manner, with the strongest effect in Huh-7 cells at 20 μM for 72 h[2].
23-Hydroxybetulinic acid (1.25-20 μM; 2-3 weeks) inhibits colony formation of Huh-7, Hep3B, and Li-7 human HCC cells over 2-3 weeks, with the strongest effect in Huh-7 cells[2].
23-Hydroxybetulinic acid (5-20 μM; 48 h) promotes apoptosis of human HCC Huh-7 cells after 48 h in a concentration-dependent manner, and this effect is reversed by Bcl-2 overexpression[2].
23-Hydroxybetulinic acid (5-20 μM) modulates apoptosis-related protein expression in human HCC Huh-7 cells, upregulating Bax and downregulating Bcl-2 and cleaved caspase-3 in a concentration-dependent manner[2].
23-Hydroxybetulinic acid (5-20 μM) modulates migration/invasion and MAPK pathway-related protein expression in human HCC Huh-7 cells, decreasing MMP2, MMP9, p-MEK1/2, and p-ERK1/2 while increasing TIMP2 in a concentration-dependent manner[2].
23-Hydroxybetulinic acid (5-20 μM; 48 h) inhibits migration invasionof human HCC Huh-7 cells after 48 h in a concentration-dependent manner[2].
23-Hydroxybetulinic acid (48 h) dose-dependently inhibits the growth of NCI-H460, SGC7901, HepG2, and sarcoma 180 cells with average IC50 values of 49.2 μM, 49.1 μM, 306.4 μM, and 28.0 μM, respectively[3].
23-Hydroxybetulinic acid (0.2-20 μM; 48 h) dose-dependently increases ADR cytotoxicity to P-gp-overexpressing MCF-7/ADR human breast carcinoma cells, reducing cell survival[4].
23-Hydroxybetulinic acid (0.2-20 μM; 48 h) dose-dependently increases VCR cytotoxicity to P-gp-overexpressing MCF-7/ADR human breast carcinoma cells, reducing cell survival[4].
23-Hydroxybetulinic acid (2-20 μM) dose-dependently increases ADR-induced apoptosis in P-gp-overexpressing MCF-7/ADR human breast carcinoma cells[4].
23-Hydroxybetulinic acid (0.2-20 μM; 1 h) dose-dependently increases intracellular ADR accumulation in P-gp-overexpressing MCF-7/ADR human breast carcinoma cells[4].
23-Hydroxybetulinic acid (0.2-20 μM; 1 h) dose-dependently increases intracellular VCR accumulation in P-gp-overexpressing MCF-7/ADR human breast carcinoma cells[4].
23-hydroxybetulinic acid (6.25-100 μM; 6, 12, 24, 48 h) potently inhibits HL-60 cell proliferation in a dose- and time-dependent manner, with an IC50 of 20.12 μM at 48 h[5].
23-hydroxybetulinic acid (12.5 μM; 24 h) induces formation of autophagic vacuoles in HL-60 cells[5].
23-hydroxybetulinic acid (12.5-50 μM; 24 h) arrests HL-60 cells at the G1 phase of the cell cycle, with increasing G1 phase occupancy at higher concentrations[5].
23-hydroxybetulinic acid (12.5-50 μM; 6, 12, 24 h) induces autophagic apoptosis in HL-60 cells in vitro in a time- and dose-dependent manner, with rates ranging from 11.60% to 78.73% across tested concentrations and times[5].
23-hydroxybetulinic acid upregulates beclin-1 mRNA expression in HL-60 cells in vitro in a dose-dependent manner[5].
23-Hydroxybetulinic acid (0.2-20 μM; 24 h) concentration-dependently reduces Doxorubicin-induced cytotoxicity in rat H9c2 cells, increasing the IC50 of Doxorubicin to 12.94, 17.67, and 26.55 μM at concentrations of 0.2, 2, and 20 μM (for 24 h) respectively[6].
23-Hydroxybetulinic acid (2.5-40 μM; 48 h) is non-toxic to THP-1-derived M0 macrophages at concentrations up to 20 μM after 48 h of incubation[7].
23-Hydroxybetulinic acid (10-20 μM; 48 h) concentration-dependently inhibits IL-4-induced M2 polarization of THP-1-derived macrophages, as measured by reduced CD206 expression after 48 h of incubation[7].
23-Hydroxybetulinic acid (10-20 μM; 48 h) concentration-dependently downregulates mRNA levels of M2-associated genes (CD206, Arg1, IL-10, CCL2) in IL-4-stimulated THP-1-derived macrophages after 48 h of incubation[7].
23-Hydroxybetulinic acid (10-20 μM; 48 h) concentration-dependently inhibits IL-4-induced STAT6 phosphorylation and nuclear translocation in THP-1-derived macrophages after 48 h of incubation, via direct binding to STAT6[7].
23-Hydroxybetulinic acid (20 μM; 48 h) inhibits IL-4-induced M2 polarization of THP-1-derived macrophages in a STAT6-dependent manner after 48 h of incubation with IL-4[7].
23-Hydroxybetulinic acid (10-20 μM; 48 h) concentration-dependently inhibits IL-4-induced IL-10 secretion by THP-1-derived macrophages, as measured in conditioned medium after 72 h of serum-free culture following 48 h of 23-HBA incubation[7].
23-Hydroxybetulinic acid (20 μM; 48 h) inhibits the IL-10/STAT3/Bcl-2 signaling pathway in 5-FU-treated SW480 colorectal cancer cells cultured in conditioned medium from 23-HBA-treated macrophages, after 48 h of 5-FU incubation[7].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human chronic myelogenous leukemia K562 cells, mouse melanoma B16 cells, human cervical carcinoma HeLa cells, human umbilical vein endothelial HUVEC cells
-
Concentration:0-300 μM
-
Incubation Time:48 h
-
Result:Inhibited proliferation of K562 cells with an IC50 of 39.9 μM, B16 cells with an IC50 of 78.5 μM, HeLa cells with an IC50 of 80.0 μM, and HUVEC cells with an IC50 of 94.8 μM.
Caused decreased cell population and morphological shrinkage in K562 cells.
-
Cell Line:human chronic myelogenous leukemia K562 cells
-
Concentration:20 μM; 40 μM; 80 μM
-
Incubation Time:24 h
-
Result:Increased the percentage of K562 cells in S phase from 26.35% (untreated) to 31.6%, 32.81%, and 52.34% at 20, 40, and 80 μM, respectively.
Reduced G0/G1 and G2/M phase populations in a concentration-dependent manner.
-
Cell Line:human chronic myelogenous leukemia K562 cells
-
Concentration:20 μM; 40 μM; 80 μM
-
Incubation Time:24 h
-
Result:Caused concentration-dependent increases in nuclear condensation (bright blue fluorescence) and uptake of PI (red fluorescence, indicating necrotic/advanced apoptotic cells) in K562 cells.\nIncreased total apoptotic K562 cells to 8.3%, 11.4%, and 18.2% at 20, 40, and 80 μM, respectively, compared to 3.8% in untreated cells.
-
Cell Line:human chronic myelogenous leukemia K562 cells
-
Concentration:10 μM; 20 μM; 40 μM; 80 μM
-
Incubation Time:24 h
-
Result:Increased pro-apoptotic Bax, cytosolic cytochrome C, cleaved caspase-9, and cleaved caspase-3 levels in a concentration-dependent manner.
Decreased anti-apoptotic Bcl-2 and survivin levels in a concentration-dependent manner.
-
Cell Line:Huh-7, Hep3B, Li-7 (human hepatocellular carcinoma cell lines)
-
Concentration:1.25 μM; 2.5 μM; 5 μM; 10 μM; 20 μM
-
Incubation Time:48 h; 72 h
-
Result:Significantly inhibited viability of Huh-7, Hep3B, and Li-7 cells in a time- and concentration-dependent manner.
Caused a more pronounced decline in cell viability at 20 μM for 72 h than for 48 h, with the strongest inhibitory effect observed in Huh-7 cells.
-
Cell Line:Huh-7 (human hepatocellular carcinoma cell line)
-
Concentration:5 μM; 10 μM; 20 μM
-
Incubation Time:48 h
-
Result:Caused dose-dependent nuclear shrinkage, cytoplasmic/nuclear fractionation, and formation of apoptotic bodies in Huh-7 cells, with increased numbers of apoptotic cells at higher concentrations.\nIncreased the apoptosis rate of Huh-7 cells in a concentration-dependent manner.
Had its pro-apoptotic effect reversed by overexpression of Bcl-2.
-
Cell Line:Huh-7 (human hepatocellular carcinoma cell line)
-
Concentration:5 μM; 10 μM; 20 μM
-
Incubation Time:48 h
-
Result:Inhibited migration of Huh-7 cells in a concentration-dependent manner, with more pronounced inhibition at higher concentrations.
-
Cell Line:Huh-7 (human hepatocellular carcinoma cell line)
-
Concentration:5 μM; 10 μM; 20 μM
-
Incubation Time:48 h
-
Result:Inhibited invasion of Huh-7 cells in a concentration-dependent manner, with more pronounced inhibition at higher concentrations.
-
Cell Line:HL-60
-
Concentration:12.5 μM
-
Incubation Time:24 h
-
Result:Induced formation of numerous autophagic vacuoles and empty vacuoles in treated cells.
-
Cell Line:HL-60
-
Concentration:12.5-50 μM
-
Incubation Time:6, 12, 24 h
-
Result:Induced autophagic apoptosis with rates of 11.60% (12.5 μM, 6 h), 17.49% (12.5 μM, 12 h), 28.37% (12.5 μM, 24 h), 25.90% (25 μM, 6 h), 49.00% (25 μM, 12 h), 72.20% (25 μM, 24 h), 28.17% (50 μM, 6 h), 60.69% (50 μM, 12 h), 78.73% (50 μM, 24 h).
-
Cell Line:rat H9c2 cells
-
Concentration:0.2, 2, 20 μM
-
Incubation Time:24 h
-
Result:Increased the IC50 of doxorubicin from 11.65 μM to 12.94, 17.67, and 26.55 μM respectively.
Concentration-dependently improved the viability of doxorubicin-treated cells.
-
Cell Line:THP-1-derived macrophages
-
Concentration:10-20 μM (co-incubated with IL-4)
-
Incubation Time:48 h
-
Result:Concentration-dependently reduced the IL-4-induced upregulation of CD206, Arg1, IL-10, and CCL2 mRNA levels.
-
Cell Line:THP-1-derived macrophages
-
Concentration:10-20 μM (co-incubated with IL-4)
-
Incubation Time:48 h
-
Result:Concentration-dependently reduced IL-4-induced STAT6 phosphorylation with no effect on JAK2 phosphorylation.
Inhibited nuclear translocation of p-STAT6.
Bound to STAT6 with a docking score of -7.04, forming hydrogen bonds with Glu 219, Gln 281, and Pro 279 residues.
In Vivo
23-Hydroxybetulinic acid (20-100 mg/kg; i.g.; daily; 7 consecutive days; 1 hour prior to Doxorubicin (HY-15142) when in combination) alone has no significant in vivo antitumor activity in sarcoma 180-bearing mice, but when co-administered with doxorubicin, it produces synergistic antitumor effects (52% and 59% tumor weight reduction at 20 mg/kg and 100 mg/kg, respectively), increases intra-tumor doxorubicin accumulation, inhibits Doxorubicin-induced P-gp up-regulation, and alleviates Doxorubicin-induced cardiotoxicity[3].
23-Hydroxybetulinic acid (20-80 mg/kg/day; i.g.; daily) dose-dependently alleviates Doxorubicin-induced cardiotoxicity in male Balb/c mice, with the 80 mg/kg/day oral dose reducing heart Doxorubicin accumulation by 46.52% and improving left ventricular ejection fraction to 75.68%[6].
23-Hydroxybetulinic acid (7.5-15 mg/kg; i.p.; daily) inhibits M2 macrophage polarization via STAT6 signaling in mice, slightly reduces colorectal tumor weight alone, and enhances 5-Fluorouracil (5-FU) (HY-90006)'s anti-tumor efficacy by approximately 80% when co-administered, without causing obvious toxicity[7].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude mice (male, 4-6 weeks old, 18-20 g, subcutaneously injected with HCC cells)[2]
-
Dosage:10 mg/kg/day; 20 mg/kg/day
-
Administration:daily; 4 weeks
-
Result:Reduced tumor volume and weight, with 20 mg/kg producing a more pronounced decline.
Reduced positive expression of Ki-67, MMP2, and MMP9, and increased positive expression of cleaved caspase-3 in tumor tissues of mice treated with 20 mg/kg.
Reduced the number of metastatic lung nodules in mice treated with 10 mg/kg, and eliminated almost all lung nodules in mice treated with 20 mg/kg.
Reduced the percentage of CD11b+Gr1+ myeloid-derived suppressor cells (MDSCs) in a concentration-dependent manner.
Caused no obvious body weight loss or pathological lesions in heart, liver, spleen, lung, or kidney tissues with either dose.
-
Animal Model:ICR (male, 18-22 g)[3]
-
Dosage:20 mg/kg; 100 mg/kg
-
Administration:i.g.; daily; 7 consecutive days; 1 hour prior to Doxorubicin when in combination
-
Result:Exerted no significant inhibitory effects on tumor weight when administered alone at 20 mg/kg or 100 mg/kg.
Reduced tumor weight by 52% when co-administered with Doxorubicin at 20 mg/kg.
Reduced tumor weight by 59% when co-administered with doxorubicin at 100 mg/kg; both combination groups showed significantly better therapeutic efficacy than Doxorubicin alone.
Dose-dependently increased intra-tumor Doxorubicin concentration, with the 100 mg/kg dose producing a statistically significant increase.
Had no effect on P-gp expression in tumors when administered alone.
Significantly prevented doxorubicin-induced up-regulation of P-gp expression at 20 mg/kg and 100 mg/kg.
Resulted in normal cardiac morphology when used in combination treatment, alleviating Doxorubicin-induced myocardial hemorrhagic spots.
Caused no significant differences in mouse body weight across groups.
-
Animal Model:BALB/c (male, 6-8 weeks old, 20±2 g, subcutaneous injection of 2×106 CT26 cells)[7]
-
Dosage:7.5 mg/kg; 15 mg/kg
-
Administration:i.p. (daily); i.p. (once every 3 days, 5-FU)
-
Result:Slightly reduced tumor weight at 7.5 mg/kg or 15 mg/kg monotherapy.
Reduced tumor weight by approximately 80% when co-administered with 5-FU at 15 mg/kg compared to the model group.
Significantly reduced tumor weight when co-administered with 5-FU at 7.5 mg/kg compared to the model group.
Did not cause significant changes in body weight, thymus index, or spleen index with monotherapy and co-treatment compared to relevant control groups.
Significantly reduced the percentage of p-STAT6-positive area and CD206-positive area in tumor tissues at 7.5 mg/kg and 15 mg/kg compared to the model group.
Induced significantly lower IL-10 mRNA levels and Bcl-2 expression in tumor tissues in the 15 mg/kg plus 5-FU group compared to the 5-FU monotherapy group.
Chemical Information
-
CAS No. 85999-40-2
-
Appearance Solid
-
Molecular Weight 472.70
-
Formula C30H48O4
-
Color White to off-white
-
SMILES
OC([C@]1(CC[C@H]2C(C)=C)[C@@]2([H])[C@](CC[C@@]3([H])[C@]4(CC[C@]5([H])[C@@]3(CC[C@H](O)[C@@]5(C)CO)C)C)([H])[C@@]4(C)CC1)=O
-
Synonyms
Anemosapogenin
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (211.55 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cytoplasmic-Nuclear Fractionated Protein Extraction
Cytoplasmic-nuclear fractionated protein extraction separates soluble cytoplasmic proteins from nuclear-enriched proteins by mild plasma-membrane permeabilization, differential centrifugation, washing of nuclei, and extraction of nuclear proteins for downstream immunoblotting or related molecular analysis. The readout is the relative abundance of a protein in cytoplasmic and nuclear fractions, commonly assessed by western blotting together with compartment markers such as tubulin or pyruvate kinase for cytoplasm and lamin, nucleoporin, hnRNP, H2AX, or Lamin B for nuclear fractions.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Fluorescent plasma-membrane potential dye assay
Fluorescent plasma-membrane potential dye assays measure changes in cell membrane potential using voltage-sensitive dyes whose fluorescence changes when cells depolarize or hyperpolarize. Anionic bis-oxonol dyes such as DiBAC4(3) enter depolarized cells more readily and show increased fluorescence after intracellular binding, while hyperpolarization reduces dye accumulation and fluorescence. FMP/FLIPR membrane-potential dyes are used for faster, homogeneous microplate assays of ion-channel or receptor-mediated membrane-potential changes.
-
Mitochondrial membrane-potential and mitochondrial mass staining
Mitochondrial membrane potential staining measures the electrochemical polarization across the mitochondrial inner membrane in live cells using lipophilic cationic fluorescent probes; early rhodamine-based work showed that selective mitochondrial dye accumulation is lost when the mitochondrial transmembrane potential is dissipated. JC-1 reports mitochondrial polarization by shifting from green monomer fluorescence to red J-aggregate fluorescence as dye concentration increases within energized mitochondria; therefore, the red/green fluorescence ratio is used as a relative readout of mitochondrial membrane potential. TMRE or TMRM staining provides a single-channel relative readout because these cationic rhodamine esters accumulate in polarized mitochondria, and lower fluorescence indicates reduced mitochondrial polarization when acquisition and dye-loading conditions are controlled. Mitochondrial mass staining is commonly performed with MitoTracker Green FM or related MitoTracker dyes as
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Mitochondrial membrane-potential fluorescent assay
Mitochondrial membrane potential fluorescent assays estimate ΔΨm in living cells using lipophilic cationic dyes such as TMRM, TMRE, rhodamine 123, and JC-1, which accumulate in mitochondria according to membrane polarization; loss of signal after FCCP or CCCP treatment is interpreted as mitochondrial depolarization. TMRM/TMRE and rhodamine 123 are commonly used for semi-quantitative live-cell microscopy or flow cytometry, while JC-1 can report a shift from red aggregate fluorescence to green monomer fluorescence during depolarization; interpretation requires controls because dye concentration, quenching mode, cell type, dye efflux, and mitochondrial mass can affect fluorescence independently of ΔΨm.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
CFSE Dye Dilution Proliferation Assay
The CFSE (carboxyfluorescein diacetate succinimidyl ester) dye dilution proliferation assay is based on the covalent labeling of intracellular proteins by a cell-permeant fluorescent dye that becomes fluorescent upon intracellular ester cleavage and then is stably retained within cells. As labeled cells divide, the dye is partitioned equally between daughter cells, resulting in a stepwise halving of fluorescence intensity that can be quantified by flow cytometry to determine the number of cell divisions undergone by each cell population. This fluorescence dilution approach enables quantitative tracking of lymphocyte proliferation at the single-cell level over multiple rounds of division. CFSE-based proliferation analysis has been widely applied to measure antigen-driven lymphocyte expansion in vitro, where discrete fluorescence peaks correspond to successive cell divisions and allow reconstruction of proliferative history within heterogeneous populations.
-
Dye-dilution cell tracking and proliferation staining
Dye-dilution cell tracking assays quantify cell proliferation by covalently labeling intracellular proteins with a stable fluorescent dye that is equally partitioned between daughter cells during mitosis, resulting in stepwise halving of fluorescence intensity with each cell division as measured by flow cytometry histograms. Carboxyfluorescein diacetate succinimidyl ester (CFSE) is a prototypical dye that diffuses into cells, is enzymatically converted into a fluorescent compound, and then covalently binds intracellular amine groups, producing long-lived fluorescence suitable for tracking multiple rounds of division in vitro and in vivo. Successive generations of dividing cells form discrete peaks of decreasing fluorescence intensity, enabling estimation of proliferation history, precursor frequency, and division index within heterogeneous populations. Alternative dyes such as CellTrace Violet (CTV) and far-red membrane dyes (e. g. , PKH26) follow the same dilution principle but differ
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
Colony Formation (Clonogenic) Assay
The clonogenic (colony formation) assay measures the ability of a single cell to retain reproductive viability and form a macroscopic colony, typically defined as a cluster derived from one progenitor cell after a defined growth period. This assay is widely used to evaluate cell survival after exposure to ionizing radiation or cytotoxic treatments and is considered a standard method in radiation biology for generating dose-response relationships of reproductive cell death. Colony formation reflects long-term proliferative capacity rather than short-term metabolic activity, and survival is quantified by comparing treated versus untreated conditions based on colony number and derived survival fractions.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Ki-67 Immunostaining Proliferation Assay
Ki-67 immunostaining measures the growth fraction of a cell population by detecting Ki-67, a nuclear antigen present in proliferating cells and absent in quiescent G0 cells. The readout is the percentage of Ki-67-positive nuclei among total counted cells, commonly called the Ki-67 labeling index or proliferation index.
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
Primary monocyte-to-macrophage differentiation
Primary human monocytes can be differentiated ex vivo into monocyte-derived macrophages by culturing purified blood monocytes for approximately 5-7 days in macrophage-supporting cytokine conditions; M-CSF commonly yields CD14^high/CD163^high macrophages, while GM-CSF yields a phenotypically distinct macrophage population, so the cytokine condition should be chosen according to the downstream model. The readout of successful differentiation is a combined change in morphology, adherence, surface phenotype, and function: differentiated macrophages become adherent, enlarge, acquire macrophage-associated markers such as CD14, CD68, CD163, CD206, or HLA-DR depending on culture condition, and show increased phagocytic capacity compared with starting monocytes.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
Purity & Documentation
-
Data Sheet (306 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[1]. Liu M, et al. Cytotoxicity of the compounds isolated from Pulsatilla chinensis saponins and apoptosis induced by 23-hydroxybetulinic acid. Pharm Biol. 2015;53(1):1-9. [Content Brief]
[2]. Tian D, et al. 23-hydroxybetulinic acid reduces tumorigenesis, metastasis and immunosuppression in a mouse model of hepatocellular carcinoma via disruption of the MAPK signaling pathway. Anticancer Drugs. 2022;33(9):815-825. [Content Brief]
[3]. Zheng Y, et al. 23-Hydroxybetulinic acid from Pulsatilla chinensis (Bunge) Regel synergizes the antitumor activities of doxorubicin in vitro and in vivo. J Ethnopharmacol. 2010;128(3):615-622. [Content Brief]
[4]. Liu Z, et al. Involvement of P-gp on Reversing Multidrug Resistance Effects of 23-Hydroxybetulinic Acid on Chemotherapeutic Agents. Front Pharmacol. 2021 Dec 15;12:796745. [Content Brief]
[5]. Ye B, et al. 23-hydroxybetulinic acid-induced HL-60 cell autophagic apoptosis and its molecular mechanism. Nat Prod Res. 2012;26(11):1063-8. [Content Brief]
[6]. Zhou F, et al. Protective effect of 23-hydroxybetulinic acid on doxorubicin-induced cardiotoxicity: a correlation with the inhibition of carbonyl reductase-mediated metabolism. Br J Pharmacol. 2015;172(23):5690-5703. [Content Brief]
[7]. Fan Z, et al. 23-Hydroxybetulinic acid attenuates 5-fluorouracil resistance of colorectal cancer by modulating M2 macrophage polarization via STAT6 signaling. Cancer Immunol Immunother. 2024;73(5):83. Published 2024 Mar 30. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1155 mL | 10.5775 mL | 21.1551 mL | 52.8877 mL |
| 5 mM | 0.4231 mL | 2.1155 mL | 4.2310 mL | 10.5775 mL | |
| 10 mM | 0.2116 mL | 1.0578 mL | 2.1155 mL | 5.2888 mL | |
| 15 mM | 0.1410 mL | 0.7052 mL | 1.4103 mL | 3.5258 mL | |
| 20 mM | 0.1058 mL | 0.5289 mL | 1.0578 mL | 2.6444 mL | |
| 25 mM | 0.0846 mL | 0.4231 mL | 0.8462 mL | 2.1155 mL | |
| 30 mM | 0.0705 mL | 0.3526 mL | 0.7052 mL | 1.7629 mL | |
| 40 mM | 0.0529 mL | 0.2644 mL | 0.5289 mL | 1.3222 mL | |
| 50 mM | 0.0423 mL | 0.2116 mL | 0.4231 mL | 1.0578 mL | |
| 60 mM | 0.0353 mL | 0.1763 mL | 0.3526 mL | 0.8815 mL | |
| 80 mM | 0.0264 mL | 0.1322 mL | 0.2644 mL | 0.6611 mL | |
| 100 mM | 0.0212 mL | 0.1058 mL | 0.2116 mL | 0.5289 mL |